Princeton Capital Management LLC Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Princeton Capital Management LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 48,287 shares of the company’s stock after selling 753 shares during the period. Novo Nordisk A/S makes up approximately 1.3% of Princeton Capital Management LLC’s holdings, making the stock its 16th largest holding. Princeton Capital Management LLC’s holdings in Novo Nordisk A/S were worth $4,154,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. ICW Investment Advisors LLC lifted its stake in Novo Nordisk A/S by 1.2% in the fourth quarter. ICW Investment Advisors LLC now owns 41,142 shares of the company’s stock worth $3,539,000 after purchasing an additional 472 shares during the last quarter. Woodmont Investment Counsel LLC raised its holdings in shares of Novo Nordisk A/S by 276.2% in the fourth quarter. Woodmont Investment Counsel LLC now owns 110,551 shares of the company’s stock worth $9,510,000 after buying an additional 81,163 shares during the period. Congress Wealth Management LLC DE lifted its stake in shares of Novo Nordisk A/S by 7.8% during the 4th quarter. Congress Wealth Management LLC DE now owns 18,079 shares of the company’s stock worth $1,555,000 after acquiring an additional 1,303 shares during the last quarter. Dillon & Associates Inc. boosted its holdings in Novo Nordisk A/S by 1.4% during the 4th quarter. Dillon & Associates Inc. now owns 287,476 shares of the company’s stock valued at $24,723,000 after acquiring an additional 4,059 shares during the period. Finally, Mosley Wealth Management grew its position in Novo Nordisk A/S by 22.2% in the 4th quarter. Mosley Wealth Management now owns 4,912 shares of the company’s stock valued at $413,000 after acquiring an additional 892 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $75.30 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $337.91 billion, a price-to-earnings ratio of 22.89, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The firm has a 50 day moving average of $83.16 and a 200 day moving average of $100.35. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NVO. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.